HOME >> MEDICINE >> NEWS
Study evaluates the effectiveness of Aripiprazole in adolescents with schizophrenia

(SAN DIEGO, MAY 23, 2007) In a six-week study in adolescents (13-17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) atypical antipsychotic aripiprazole demonstrated significant improvement compared to placebo on the primary efficacy endpoint, Positive and Negative Syndrome Scale (PANSS) Total Score. In the findings first presented here at the 160th annual meeting of the American Psychiatric Association, approximately 85 percent of patients completed this six-week study. (1), (2)

"Data on the management of schizophrenia in adolescents are limited," said Robert Findling, M.D., Director of Child and Adolescent Psychiatry, University Hospitals Case Medical Center, Cleveland, Ohio. "The findings from this study contribute important new information about schizophrenia in adolescents."

Study Design and Findings

The findings are from a six-week, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of aripiprazole in adolescents, 13-17 years-old, with a primary diagnosis of schizophrenia. This study, sponsored by Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, NJ) was conducted at 101 centers in 13 countries with 302 ethnically diverse adolescents. After a minimum three-day washout period without any antipsychotic treatment, adolescents were randomly assigned to receive one of two fixed doses of aripiprazole [10 mg/day (n=100) or 30 mg/day (n=102)] or placebo (n=100). Aripiprazole was started at 2 mg/day and titrated to the target dose. The primary efficacy endpoint was the mean change from baseline to endpoint (Week Six) in the PANSS Total Score. Secondary endpoints included the PANSS positive and negative subscales and the Clinical Global Impression of Improvement (CGI-I) scale. Important safety measures included incidence of adverse events
'"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Otsuka America Pharmaceutical, Inc.
23-May-2007


Page: 1 2 3

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2020)... ... March 27, 2020 , ... During a time of global distress and concern about the impact ... the UNITE HERE Education and Support Fund in an effort to assist hospitality ... HERE represents 300,000 working people in the food service , hotel ...
(Date:3/22/2020)... , ... March 21, 2020 , ... ... announces easy-to-implement solutions that hospitals, medical organizations, and health centers can use for ... to the coronavirus pandemic, many medical professionals are working around the clock to ...
(Date:3/20/2020)... ... 20, 2020 , ... My heart goes out to those across our nation ... a loved one recently through similar circumstances - underlying conditions compounded by a virus ... a gamut of negative emotions just like many have: fear, anxiety, uncertainty. In contrast, ...
(Date:3/20/2020)... ... March 21, 2020 , ... The Healthcare Compliance Symposium ... day of live discussion and learning online. Experts will provide helpful insight on ... the role of boards, fraud, waste and abuse, and privacy and security laws ...
(Date:3/19/2020)... ... March 19, 2020 , ... Sucheta Kamath, Founder and ... a free Student Learning Exercise: ExQ® Superpower Hour. During the recent ... resources to help with the immediate need for activities that can be implemented ...
Breaking Medicine News(10 mins):
(Date:3/27/2020)... ... March 27, 2020 , ... Nexus, a national nonprofit ... name to Nexus Family Healing. For more than 45 years, Nexus has focused ... from mental, emotional and behavioral issues. Moving forward, Nexus Family Healing will fulfill ...
(Date:3/27/2020)... ... March 27, 2020 , ... PTS Diagnostics, a U.S.-based ... appointed as President and Chief Executive Officer. , Mr. Chapman brings 20 years ... of ARKRAY USA, Inc. He joins PTS Diagnostics with an accomplished track record ...
(Date:3/20/2020)... ... March 20, 2020 , ... Suntuity Solar ( https://suntuitysolar.com ... US headquarters in New Jersey, recently launched a new initiative in response to ... in the local communities across New Jersey, Maryland and Florida. “The Suntuity Pledge” ...
Breaking Medicine Technology:
Cached News: